Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Intravesical Talimogene Laherparepvec for Non-Muscle Invasive Transitional Cell Carcinoma

NCT03430687 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT03430687
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03430687 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Intravesical Talimogene Laherparepvec for Non-Muscle Invasive Transitional Cell Carcinoma
Lead sponsor
University of California, San Francisco
Phase
Phase 1
Overall status
Withdrawn
Start date
June 1, 2018
Completion date
December 31, 2020
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stage 0 bladder urothelial carcinoma ajcc v6 and v7, stage 0a bladder urothelial carcinoma ajcc v6 and v7, stage 0is bladder urothelial carcinoma ajcc v6 and v7, stage i bladder urothelial carcinoma ajcc v6 and v7